Major Depressive Disorder (MDD)Phase 1NCT05416957
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
A Phase 1 study testing Vortioxetine Hemihydrobromide Orally Disintegrating Tablets in people with Major Depressive Disorder (MDD), run by Seasons Biotechnology (Taizhou) Co., Ltd. at 1 site in India.
Trial summary
An open label, randomized, two-period, two-treatment [Treatment A (Investigational product administration under fasting condition) vs Treatment B (Investigational product administration under fed condition)], two-sequence, crossover, balanced, single dose oral food effect bioavailability study. Read more about this study
- Who is it for?
- Ages 25 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Major Depressive Disorder (MDD)
- What is being tested?
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteIndia
- Study dates
- 18 Sep 2022to 27 Oct 2022
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 25 to 45 years old, both inclusive.
- Gender: Male and/or non-pregnant, non-lactating female. A. Female of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to first dosing day. They must be using an acceptable form of contraception.
- For female of childbearing potential, acceptable forms of contraception include the following:
- Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, or iii. Surgical sterilization or iv. Practicing sexual abstinence throughout the course of the study.
- Female will not be considered of childbearing potential if one of the following is reported and documented on the medical history:
- Postmenopausal with spontaneous amenorrhea for at least one year, or ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iii. Total hysterectomy and an absence of bleeding for at least 3 months.
Show all 14Show fewer
- BMI: 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
- Able to communicate effectively with study personnel.
- Willing to provide written informed consent to participate in the study.
- All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include:
- A physical examination (clinical examination) with no clinically significant finding.
- Results within normal limits or clinically non-significant for the following tests:
- Additional tests and/or examinations (apart from mentioned in protocol) may be performed, if necessary, based on principal investigator discretion.
- All results will be assessed against the current laboratory normal ranges at the time of testing and a copy of the normal ranges used will be included in the study documentation.
Who cannot join
- History of allergic responses to Vortioxetine or other related drugs, or any of its formulation ingredients.
- Have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, ECG, chest X-ray recording, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)].
- Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
- History or presence of bronchial asthma.
- Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.
- A depot injection or implant of any drug within 3 months prior to the first dose of study medication.
Show all 28Show fewer
- Use of CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see https://drug-interactions.medicine.iu.edu/MainTable.aspx).
- History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
- Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period.
- History of difficulty with donating blood or difficulty in accessibility of veins.
- A positive hepatitis screen (includes subtypes B \& C).
- A positive test result for HIV antibody and / or syphilis (RPR).
- Volunteers who have received a known investigational drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
- Volunteers who have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
- History of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption.
- Intolerance to venipuncture
- Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.
- Institutionalized volunteers.
- Use of any prescribed medications (including Mono Amine Oxidase Inhibitors, serotonergic antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or other drugs that affect coagulation) within 14 days prior to the first dose of study medication.
- Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
- Use of grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
- Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), cigarettes and tobacco containing products, recreational drugs, alcohol or other alcohol containing products within 48 hours prior to the first dose of study medication.
- Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
- History of (or have a family history of) bipolar disorder or suicidal thoughts or actions or any other psychiatric problems.
- History of seizures or convulsions.
- Symptoms of acute narrow-angle glaucoma.
- Volunteer having serum sodium value is less than lower limit of normal reference ranges during screening.
- History of bleeding problems.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Single Dose Oral Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg in Healthy Adult Human Subjects Under Fasting and Fed Conditions
An open label, randomized, two-period, two-treatment [Treatment A (Investigational product administration under fasting condition) vs Treatment B (Investigational product administration under fed condition)], two-sequence, crossover, balanced, single dose oral food effect bioavailability study.
Read the detailed description
Single dose oral food effect bioavailability study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg in healthy adult human subjects under fasting and fed conditions.
- To compare and evaluate the oral bioavailability of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg in healthy, adult, human subjects under fasting and fed conditions.
- To monitor the safety and tolerability of the subjects. An open label, randomized, two-period, two-treatment [Treatment A (Investigational product administration under fasting condition) vs Treatment B (Investigational product administration under fed condition)], two-sequence, crossover, balanced, single dose oral food effect bioavailability study.
- Conditions
- Major Depressive Disorder (MDD)
- Being tested
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
- Medical subject headings
- Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vortioxetine Hemihydrobromide Orally Disintegrating TabletsDrug
Also called SF001 ODT
Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
| Study group | Role | What they receive |
|---|---|---|
| SF001 ODT administered under fasting condition | Experimental | Investigational product administration under fasting condition Receives: Drug: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets |
| SF001 ODT administration under fed condition | Experimental | Investigational product administration under fed condition Receives: Drug: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma samples will be tested. PK parameters Cmax on FED and FAST conditions will be reported. Ratios of PK parameters on FED and FAST fall within 80.00% to 125.00%
PK parameters will be determined using a non-compartmental analysis. Absence of food effect will be concluded if the 90% confidence intervals of the Treatment B (Investigational product administration under fed condition) / Treatment A (Investigational product administration under fasting condition) ratios of relative mean (Geometric mean) of Vortioxetine fall within 80.00% to 125.00% for Ln-transformed Cmax
Measured: In each period, total 28 blood samples will be collected at pre-dose (0.0 hour) and until 240 hours post dose
Plasma samples will be tested. PK parameters AUCi on FED and FAST conditions will be reported. Ratios of PK parameters on FED and FAST fall within 80.00% to 125.00%
PK parameters will be determined using a non-compartmental analysis. Absence of food effect will be concluded if the 90% confidence intervals of the Treatment B (Investigational product administration under fed condition) / Treatment A (Investigational product administration under fasting condition) ratios of relative mean (Geometric mean) of Vortioxetine fall within 80.00% to 125.00% for Ln-transformed AUCi
Measured: In each period, total 28 blood samples will be collected at pre-dose (0.0 hour) and until 240 hours post dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2022
- Study start18 Sep 2022
- Primary completion27 Oct 2022
- Study completion27 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Major Depressive Disorder (MDD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Minesh Patel, Ph.D., Principal investigator, Cliantha Research Limited
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05416957
- Sponsor's protocol ID
- C1B02240
- Status last verified
- Apr 2023
- First submitted
- 6 Jun 2022
- Last updated
- 13 Apr 2023
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No